Exelixis | EXEL - Interest Expense On Debt

Stock Price
43.08
Daily Change
0.27 0.63%
Monthly
1.60%
Yearly
30.07%
Q1 Forecast
40.09

Exelixis reported $23.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Amgen USD 685M 9M Sep/2025
AstraZeneca USD 303M 38M Jun/2025
Bayer EUR 762M 267M Sep/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Eisai JPY 1.44B 526M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 37M 28M Sep/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 327M 22M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
Sanofi EUR -25M 99.78M Dec/2025
Takeda JPY 123.63B 40.49B Dec/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Xencor USD 7.66M 578K Sep/2025